Search

Displaying results 5161 - 5170 of 7018 in total
  1. Drug

    TO-901317

    go.drugbank.com/drugs/DB07080
    Experimental

    TO-901317 is an LXRalpha and LXRbeta agonist.

  2. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  3. Drug

    Bufotenine

    go.drugbank.com/drugs/DB01445
    ExperimentalIllicit

    Bufotenin has been used as a tool in CNS studies and misused as a psychedelic. … A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics.

    Synonyms: DM5-HTCategories: Monoamine Oxidase A Substrates
  4. Drug

    Chlorophetanol

    go.drugbank.com/drugs/DB11368
    Experimental

    Chlorophetanol is an agent known to have antifungal activities.

  5. Drug

    Ferric oxyhydroxide

    go.drugbank.com/drugs/DB14695
    Experimental

    An antiferromagnetic material; constitutes the core of natural ferritin.

  6. Drug

    Chelerythrine

    go.drugbank.com/drugs/DB17024
    Experimental

    A benzophenanthridine alkaloid evaluated as a kinase-inhibitor.[A252982]

  7. Drug

    IK-930

    go.drugbank.com/drugs/DB18149
    Investigational

    IK-930 is an oral, paralog-selective TEAD inhibitor.

  8. Drug

    ACT-451840

    go.drugbank.com/drugs/DB13054
    Investigational

    ACT-451840 has been used in trials studying Malaria.

  9. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    It is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  10. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.